ADCT — ADC Therapeutics SA

—
NYSE · Health Care · Pharmaceuticals · CIK 1771910 ·
Last close
$1.35
Market Cap
$189.89M
52W High
$4.98
52W Low
$0.78
ADV30
1,593,130
Next earnings
2026-11-09
ADC Therapeutics SA provides antibody drug conjugate (ADC) technology platform in Switzerland and the United States. Its flagship product includes ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug Administration, conditional approval from the European Commission, and conditional approval from the China National Medical Products Administration for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. The company is also seeking to continue expanding ZYNLONTA into international markets and into earlier lines of DLBCL and indolent lymphomas, including follicular lymphoma (FL) and marginal zone lymphoma (MZL) as a single agent and in combination through its LOTIS-5 confirmatory Phase 3 clinical trial and LOTIS-7 Phase 1b clinical trial, as well as through investigator-initiated trials (IITs). In addition, it is investigating a CD-22 targeted compound' and ADCT-602 that is in a Phase 1/2 IIT in refractory B-cell acute lymphoblastic leukemia. Further, the company's pre-clinical stage pipeline includes a portfolio of next generation investigational ADCs targeting Claudin-6, NaPi2b, PSMA, NaPi2b, and ASCT2. ADC Therapeutics SA was incorporated in 2011 and is headquartered in Epalinges, Switzerland.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 21,716,000 19,736,000 -14,412,000 -25,304,000 255,863,000 189,204,000 505,036,000
Jun 2026 19,248,000 16,899,000 -22,778,000 -16,565,000 279,379,000 219,107,000 507,584,000
Mar 2026 20,851,000 17,236,000 -25,245,000 -32,968,000 291,496,000 231,008,000 507,873,000
Dec 2025 23,058,000 21,359,000 -18,123,000 -6,409,000 323,150,000 261,338,000 508,984,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-100,518,000
Investing CF
$627,000
Financing CF
$54,302,000
CapEx
$-296,000
Dividends Paid
—
Buybacks
$-837,000
EPS Diluted TTM
$-0.52
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-1,710,778,000
Inventory
$5,626,000
Receivables
$28,417,000
ST Investments
—
EBIT TTM
$-29,046,000
Pretax Income TTM
$-81,650,000
Interest Exp TTM
$52,604,000
Analysts
3

Yahoo Snapshot (yfinance, live)

Total Revenue
$84,873,000
EBITDA
$-78,351,248
Free Cash Flow
$-74,586,496
Enterprise Value
$441,191,904
Total Cash
$189,204,000
Total Debt
$441,908,992
Shares Out
140,661,880
Trailing EPS
$-0.46
Book Value
$-1.95
ROE
—
ROA
-18.1%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 81,357,000 -107,207,000 -142,623,000 323,150,000 508,984,000 -185,834,000 -141,174,000
Dec 2024 70,837,000 -129,591,000 -157,846,000 321,980,000 524,622,000 -202,642,000 -123,835,000
Dec 2023 69,558,000 -165,051,000 -240,053,000 354,782,000 503,031,000 -148,249,000 -118,686,000
Dec 2022 209,908,000 -122,987,000 -157,128,000 490,859,000 411,408,000 79,451,000 -138,311,000

TTM Snapshot

Revenues TTM
$79,584,000
NetIncome TTM
$-96,908,000
OpCashFlow TTM
—
Assets (Latest)
$279,379,000
Forward EPS
$-1.49

Max Pain — expiry 2027-01-15

max pain strike: $2.50 · spot: $1.37 · call oi: 1,812 · put oi: 0
Expected Move to 2027-01-15: ±$1.60 (116.79%) — implied range $-0.23 – $2.97 · ATM straddle on $2.50 strike

Peers — same industry

TickerNameMarket CapLastDaily %
RNAC Cartesian Therapeutics, Inc. $186.68M $6.12 —
TRDA Entrada Therapeutics, Inc. $194.19M $4.96 —
SIGA SIGA TECHNOLOGIES INC $196.16M $2.73 —
WHWK Whitehawk Therapeutics, Inc. $181.75M $3.08 —
VOGX Vogenx, Inc. $200.25M $13.48 —

News headlines (Yahoo Finance, 1h cache)

ADC Therapeutics SA (ADCT) Reports Q3 Loss, Tops Revenue Estimates
2026-11-09 12:40 · Yahoo
ADC Therapeutics Reports Third Quarter 2026 Financial Results and Provides Operational Updates
2026-11-09 12:30 · Yahoo
ADC Therapeutics Reports Strong Lymphoma Responses, Plans Phase III Study
2026-11-04 23:14 · Yahoo
ADC Therapeutics Announces Abstracts at the 68th ASH Annual Meeting Highlighting Breadth of ZYNLONTA® Clinical Program
2026-11-04 14:00 · Yahoo
ADC Therapeutics to Present at November Investor Conferences
2026-11-03 12:15 · Yahoo
ADC Therapeutics Announces New Employee Inducement Grant
2026-11-02 21:05 · Yahoo
ADC Therapeutics to Announce Third Quarter 2026 Financial Results on November 9, 2026
2026-11-02 12:15 · Yahoo
ADC Therapeutics Announces ZYNLONTA® Updates in Japan
2026-10-29 11:30 · Yahoo
ADC Therapeutics Cuts Debt, Extends Runway Ahead of Key Drug Data, RBC Says
2026-10-09 15:27 · Yahoo
ADC Therapeutics Announces Comprehensive Strategic Financial Restructuring Marking Key Capital Structure Improvements
2026-10-08 13:00 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.